UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
UNITED THERAPEUTICS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$543.15+10.03 (+1.88%)
Close on Oct 19, 2026
- Market cap
- $24.88B
- P/E (TTM)
- 19.4
- Dividend yield
- –
UNITED THERAPEUTICS Corp revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Tyvaso | $1.85B | $1.87B | $1.88B | $1.83B | $1.79B | $1.71B | $1.62B | $1.56B | $1.45B | $1.37B | $1.23B | $1.13B | 58.7% | +3.7% |
| Tyvaso DPI | $1.33B | $1.32B | $1.29B | $1.23B | $1.17B | $1.11B | $1.03B | $974.10M | $904.60M | $839.90M | $731.10M | $609.60M | 42.2% | +14.3% |
| Nebulized Tyvaso | $520.70M | $549.10M | $585.70M | $602.70M | $620.10M | $605.60M | $586.80M | $581.00M | $542.50M | $527.90M | $502.60M | $515.80M | 16.5% | -16.0% |
| Orenitram | $513.60M | $511.80M | $496.90M | $483.50M | $465.60M | $448.80M | $434.30M | $410.60M | $389.40M | $377.40M | $359.40M | $351.10M | 16.3% | +10.3% |
| Remodulin | $506.80M | $515.20M | $526.80M | $533.30M | $535.70M | $548.30M | $538.10M | $518.70M | $521.50M | $501.40M | $494.80M | $502.20M | 16.1% | -5.4% |
| Unituxin | $229.00M | $222.20M | $226.80M | $232.00M | $245.20M | $238.50M | $238.70M | $225.40M | $215.60M | $208.20M | $198.90M | $181.40M | 7.3% | -6.6% |
| Adcirca | $27.10M | $26.90M | $30.00M | $26.90M | $24.20M | $23.40M | $23.80M | $25.90M | $26.20M | $28.00M | $28.90M | $32.50M | 0.9% | +12.0% |
| Other | $25.60M | $24.30M | $24.00M | $22.90M | $21.50M | $20.90M | $22.10M | $20.50M | $16.90M | $15.50M | $11.80M | $11.70M | 0.8% | +19.1% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.01B | $3.03B | $3.04B | $2.99B | $2.93B | $2.85B | $2.74B | $2.62B | $2.49B | $2.37B | $2.20B | $2.08B | 95.3% | +2.5% |
| ROW | $149.10M | $138.20M | $145.70M | $138.50M | $145.40M | $146.30M | $137.70M | $136.30M | $129.50M | $124.30M | $125.30M | $124.30M | 4.7% | +2.5% |
From the segment and revenue-disaggregation notes of United Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.